ArticleMolecular pharmaceutics2013
Long-circulating heparin-functionalized magnetic nanoparticles for potential application as a protein drug delivery platform.
Article in Molecular pharmaceutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Prospects and challenges in intracellular delivery of therapeutic proteins.Pharmacological reports : PR · 2026Review
- Potential application and prospects of ROS-sensitive biomaterials in cancer therapy: a immune microenvironment triggered nanomaterial.Discover oncology · 2025Review
- Zinc oxide nanoparticles with catalase-like nanozyme activity and near-infrared light response: A combination of effective photodynamic therapy, autophagy, ferroptosis, and antitumor immunity.Acta pharmaceutica Sinica. B · 2024Article
- Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy.Pharmaceutics · 2023Article
- The progress of research on the application of redox nanomaterials in disease therapy.Frontiers in chemistry · 2023Review
- Nanotheranostics for Image-Guided Cancer Treatment.Pharmaceutics · 2022Review
- Improvement of Transfection with PepFects Using Organic and Inorganic Materials.Methods in molecular biology (Clifton, N.J.) · 2022Article
- In Vitro and In Vivo Evaluation of PEGylated Starch-Coated Iron Oxide Nanoparticles for Enhanced Photothermal Cancer Therapy.Pharmaceutics · 2021Article
- Glycosaminoglycans: Carriers and Targets for Tailored Anti-Cancer Therapy.Biomolecules · 2021Review
- Current update on nanoplatforms as therapeutic and diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities.Asian journal of pharmaceutical sciences · 2021Review
- ICG-Loaded PEGylated BSA-Silver Nanoparticles for Effective Photothermal Cancer Therapy.International journal of nanomedicine · 2020Article
- Article
- Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents.Molecules (Basel, Switzerland) · 2018Review
- CPP-Assisted Intracellular Drug Delivery, What Is Next?International journal of molecular sciences · 2016Review
- Nanotechnology for protein delivery: Overview and perspectives.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Heparin nanoparticles for β amyloid binding and mitigation of β amyloid associated cytotoxicity.Carbohydrate research · 2015Article
- Bench-to-bedside translation of magnetic nanoparticles.Nanomedicine (London, England) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Starch-coated, PEGylated, and heparin-functionalized iron oxide magnetic nanoparticles (DNPH) were successfully synthesized and characterized in detail. The PEGylation (20 kDa) process resulted in an average coating of 430 PEG molecules per nanoparticle. After that, heparin conjugation was carried out to attain the final DNPH platform with 35.4 μg of heparin/mg of Fe. Commercially acquired heparin-coated magnetic nanoparticles were also PEGylated (HP) and characterized for comparison. Protamine was selected as a model protein to demonstrate the strong binding affinity and high loading content of DNPH for therapeutically relevant cationic proteins. DNPH showed a maximum loading of 22.9 μg of protamine/mg of Fe. In the pharmacokinetic study, DNPH displayed a long-circulating half-life of 9.37 h, 37.5-fold longer than that (0.15 h) of HP. This improved plasma stability enabled extended exposure of DNPH to the tumor lesions, as was visually confirmed in a flank 9L-glioma mouse model using magnetic resonance imaging (MRI). Quantitative analysis of the Fe content in excised tumor lesions further demonstrated the superior tumor targeting ability of DNPH, with up to 31.36 μg of Fe/g of tissue (13.07% injected dose (I.D.)/g of tissue) and 7.5-fold improvement over that (4.27 μg of Fe/g of tissue; 1.78% I.D./g of tissue) of HP. Overall, this study shed light on the potential of DNPH to be used as a protein drug delivery platform.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.